Factory 99% Venetoclax Powder CAS 1257044-40-8 Chemical Intermediate Abt-199 Venetoclax

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A726
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Venetoclax
• CAS: 1257044-40-8
• Appearance: Yellow Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Venetoclax
Appearance	Yellow Powder
CAS NO.	1257044-40-8
MF	C45H50ClN7O7S
Storage	Keep in a cool, dry, dark location

 

Venetoclax is a targeted therapy medication that selectively inhibits the B-cell lymphoma-2 (BCL-2) protein. It is primarily used in the treatment of various hematological cancers by promoting apoptosis (programmed cell death) in cancer cells that overexpress BCL-2.

 

1. Chronic Lymphocytic Leukemia (CLL): Venetoclax is utilized as a monotherapy or in combination with other agents for patients with CLL who have received prior therapies or as a first-line treatment in specific circumstances.

2. Acute Myeloid Leukemia (AML): In combination with hypomethylating agents or low-dose cytarabine, venetoclax is indicated for the treatment of adults with newly diagnosed AML who are ineligible for intensive induction chemotherapy.

3. Small Lymphocytic Lymphoma (SLL): Similar to its use in CLL, venetoclax can be prescribed for patients with SLL, as both conditions share overlapping pathological features and are often managed similarly.

1. Selective BCL-2 Inhibition: Venetoclax binds specifically to the BCL-2 protein, preventing it from inhibiting the apoptotic process. This allows cancer cells, which often rely on BCL-2 for survival, to undergo programmed cell death.

2. Synergistic Effect with Other Therapies: When combined with other chemotherapy agents or targeted therapies, venetoclax enhances the overall cytotoxic effect on cancer cells, leading to improved clinical outcomes such as increased remission rates and prolonged survival.

3. Minimal Off-Target Effects: Due to its high selectivity for BCL-2, venetoclax generally exhibits fewer off-target effects compared to broader-spectrum apoptosis inducers, resulting in a more favorable safety profile with manageable side effects.